drugset / Trial / NCT05655221
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety, tolerability, and immunogenicity of B1344 by single subcutaneous (s.c.) injection in healthy subjects
Timeline
- Start
- 2022-08-30
- Primary completion
- 2023-07-31
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | B1344 | Protein / enzyme biologic | 2 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 5 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 30 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 45 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 60 mg | Subcutaneous |
| Comparator | B1344 | Protein / enzyme biologic | 80 mg | Subcutaneous |